Targeted therapy in antiphospholipid syndrome.

Area of Science:

• Immunology
• Rheumatology
• Hematology

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder linked to antiphospholipid antibodies (aPL).
• Clinical manifestations include thrombosis and pregnancy complications.
• Current treatment relies on vitamin K antagonists for long-term anticoagulation.

Purpose of the Study:

• To review emerging therapeutic targets for aPL-mediated conditions.
• To explore the development of safer, targeted therapies for APS.

Main Methods:

• Review of current research on novel therapeutic strategies.
• Identification of potential targets for aPL-mediated diseases.

Main Results:

• Investigational therapies include anti-CD20 monoclonal antibodies and new anticoagulants (direct thrombin and anti-Xa inhibitors).
• Research is exploring interference with aPL-mediated cell activation and complement component targeting.
• Novel approaches include blocking pathogenic aPL subpopulations with tailored peptides.

Conclusions:

• APS management is limited by current anticoagulation options.
• Promising novel targets are under investigation for APS.
• Prospective randomized controlled trials are needed to validate new therapies for clinical practice.